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ABSTRACT
This review considers whether probiotics are effective agents for the treatment and ⁄ or prevention of
bacterial vaginosis (BV). There seems to be an association between the absence of, or low concentrations
of, vaginal lactobacilli and the development of BV. Many studies have suggested that the presence of
H2O2-producing vaginal lactobacilli may protect against BV, although some studies do not support this
hypothesis. In-vitro studies have suggested that certain speciﬁc strains of lactobacilli are able to inhibit
the adherence of Gardnerella vaginalis to the vaginal epithelium and ⁄ or produce H2O2, lactic acid and ⁄ or
bacteriocins, which inhibit the growth of bacteria causing BV. Clinical trials showed that intra-vaginal
administration of Lactobacillus acidophilus for 6–12 days, or oral administration of L. acidophilus or
Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14 for 2 months, resulted in the cure of BV
(deﬁned as a 0–1 positive score according to Amsel’s criteria), and ⁄ or reduced the recurrences of BV,
and ⁄ or caused an increase in vaginal lactobacilli and restoration of a normal vaginal microbiota,
signiﬁcantly more frequently than did a placebo, acetic acid or no treatment. However, several trials
have found no signiﬁcant difference in the cure rate of BV and in the number of vaginal lactobacilli after
intra-vaginal instillation of lactobacilli when compared with the effect of a placebo or oestrogen. Thus,
although the available results concerning the effectiveness of the administration of lactobacilli for the
treatment of BV are mostly positive, it cannot yet be concluded deﬁnitively that probiotics are useful for
this purpose.
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INTRODUCTION
Bacterial vaginosis (BV) is a common vaginal
infection causing signiﬁcant gynaecological and
obstetric morbidity. Apart from causing irritating
symptoms, mainly a malodorous vaginal dis-
charge, BV has been associated with pelvic
inﬂammatory disease [1], infections following
gynaecological surgery [2], and pre-term birth
[3]. It has also been suggested that the presence
of BV increases the risk for human immunodeﬁ-
ciency virus infection [4,5]. Treatment with met-
ronidazole or clindamycin, administered orally or
intra-vaginally, has been followed by frequent
recurrences of BV [6]. Because of its high mor-
bidity and frequent recurrence following treat-
ment, alternative therapeutic agents need to be
sought for the treatment of BV.
Probiotics are deﬁned as ‘live microorganisms
which, when administered in adequate amounts,
confer a health beneﬁt on the host’ [7]. Lactobacilli
are the commonest organisms used as probiotics.
Since the vaginal microbiota of women with BV
has been found to contain a reduced number of
lactobacilli in comparison with healthy women,
lactobacilli administered orally or intra-vaginally
have been tested for their effectiveness in colo-
nising the vagina and curing women with BV, or
at least preventing its recurrence.
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CHANGES IN VAGINAL
MICROBIOTA DURING BV
The normal vaginal microbiota is normally dom-
inated by lactobacilli, especially Lactobacillus crisp-
atus [8–11], Lactobacillus jensenii [8,11], Lactobacillus
iners [9,11,12] and Lactobacillus gasseri [8,10,11].
Compared with that of normal women, the vagi-
nal microbiota of women with BV consists more
commonly, and in higher numbers, of Gardnerella
vaginalis, Mycoplasma hominis, Prevotella, Pepto-
streptococcus, Mobiluncus and Bacteroides spp.,
while lactobacilli are found less frequently and
in lower numbers. Nugent et al. [13] suggested
that BV should be diagnosed when vaginal smears
examined following Gram’s stain are given a score
of ‡7, after adding the points (1–4+) allocated to
each of the following morphotypes: lactobacilli
(large Gram-positive rods), G. vaginalis (small
Gram-variable rods), Bacteroides spp. (small
Gram-negative rods) and Mobiluncus spp. (cur-
ved Gram-variable rods). The higher the number
of the speciﬁc morphotypes per oil immersion
ﬁeld, the higher the number of points for each
morphotype, except for lactobacilli, the absence of
which obtained the highest score.
There is strong evidence that the absence of
vaginal lactobacilli is associated with the devel-
opment of BV. Alvarez-Olmos et al. [14] found a
negative association between BV and the presence
of lactobacilli in the vaginas of females aged
14–18 years (p 0.034). Similarly, vaginal lacto-
bacilli were isolated from 73.7% of 825 women
without BV, and from 29.8% of 131 women with
BV (p <0.001) [15], from 74.3% of 2729 women
without BV, and from 38.4% of 445 women with
BV (OR 0.7, 95% CI 0.6–0.8), in a study of preg-
nant women aged >18 years [16], and from 96%
of 28 women without BV, and from 52% of 67
women with BV (p <0.001) [17].
In addition, apart from the association between
an absence of vaginal lactobacilli and BV, a
possible association between low concentrations
of vaginal lactobacilli and development of BV has
been revealed by some studies. Thus, Zariffard
et al. [18] analysed the cervicovaginal lavage sam-
ples of 21 human immunodeﬁciency virus-posit-
ive women by real-time PCR, and found that the
median number of lactobacilli was signiﬁcantly
lower and the median number of G. vaginalis
organisms was signiﬁcantly higher in ﬁve women
with BV, compared with 16 women without BV
(8.5 · 106 vs. 1.1 · 109, p 0.013, and 1.3 · 1010 vs.
5.4 · 107, p 0.004, respectively). Mikamo et al. [19]
also found that themean count of Lactobacillus spp.
was signiﬁcantly lower in 129 G. vaginalis-positive
women than in 110 G. vaginalis-negative women
(7.02 vs. 8.66 log10 CFU ⁄ g, p <0.0001).
It has been suggested that H2O2-producing vagi-
nal lactobacilli may prevent infection of the vaginal
epithelium by bacteria that cause BV. Eschenbach
et al. [17] isolated facultative H2O2-producing vagi-
nal lactobacilli from 27 (96%) of 28 women without
BV, and from four (6%) of 67 women with BV
(p <0.001). In a study of pregnant women by
Hillier et al. [20], H2O2-producing lactobacilli were
isolated from 5% of women with BV (based on the
Nugent score) and from 61% of those with a
normal microbiota (p <0.001). A second study of
pregnant women by Hillier et al. [21] showed that
BV (based on Amsel’s criteria) was signiﬁcantly
less common among women with H2O2-produc-
ing vaginal lactobacilli (10 ⁄ 127, 8%) than among
women with non-H2O2-producing or no lactoba-
cilli (29 ⁄ 86, 34%, and 37 ⁄ 62, 60%, respectively;
p <0.001 for both comparisons). Similarly, Hawes
et al. [22] found that BV developed in ten (25%) of
40 women with non-H2O2-producing vaginal
lactobacilli, compared with only three (3%) of
118 women with H2O2-producing lactobacilli
(p 0.02). Furthermore, a study by Antonio et al.
[8] found that women with vaginal L. crispatus or
L. jensenii (>94% of which were found to produce
H2O2) were signiﬁcantly less likely to have BV
than were women colonised by other lactobacilli
(only 22% of which produced H2O2) or women
with no vaginal lactobacilli.
In contrast, some studies do not support the
protective role of H2O2-producing lactobacilli
against BV. In the study by Alvarez-Olmos et al.
[14] amongwomenwith vaginal lactobacilli, H2O2-
producing lactobacilli were isolated from 85% of
18 women with BV, and from 15% of 43 women
without BV [14]. Moreover, Rosenstein et al. [23]
isolated H2O2-producing lactobacilli from 11
(91.7%) of 12 pregnant women whose microbiota
was indicative of BV following Gram’s stain.
IN-VITRO EVIDENCE FOR THE
EFFECT OF VAGINAL LACTOBACILLI
ON BACTERIA CAUSING BV
Some in-vitro studies have shown that speciﬁc
strains of lactobacilli are able to coaggregate with
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G. vaginalis and block the adherence and ⁄ or dis-
place previously adherent strains of G. vaginalis
from vaginal epithelial cells. Boris et al. [24]
showed that Lactobacillus acidophilus, L. gasseri
and L. jensenii, isolated from the vaginal samples
of healthy pre-menopausal women, coaggregated
in vitro with G. vaginalis. L. acidophilus was also
found to decrease the adherence and to displace
previously adherent strains of G. vaginalis on
vaginal epithelial cells. Mastromarino et al. [25]
found that human isolates of Lactobacillus salivar-
ius FV2 and L. gasseri 335 coaggregated in vitro
with G. vaginalis, and that vaginal tablets contain-
ing a combination of these organisms with Lacto-
bacillus brevis CD2 (which is strongly adherent to
epithelial cells) reduced the adhesion by 57.7%
and displaced 60.8% of G. vaginalis cells attached
previously.
Some Lactobacillus strains have also been found
to have an inhibitory effect on the in-vitro growth
of pathogens that cause BV, which may be caused,
in part, by the production of H2O2. Mastromarino
et al. [25] found that L. salivarius FV2 and L. gasseri
335, isolated from the human vagina, produced
large amounts of H2O2 and inhibited the growth
of G. vaginalis. McLean and Rosenstein [26]
showed that L. acidophilus 48101, isolated from
the vagina of healthy women, produced large
amounts of H2O2 and inhibited (although by less
than the mean + SD) the growth of Bacteroides
spp., Prevotella bivia and G. vaginalis isolated from
vaginal swabs of women with BV.
Production of lactic acid by lactobacilli, which is
mainly responsible for the low vaginal pH, con-
tributes, probably even more than production of
H2O2, to the inhibition of growth of G. vaginalis.
An in-vitro study by McLean and McGroarty [27]
showed that the bacteriostatic effect of L. acidophi-
lus on G. vaginalis NCTC 11292 was reduced by
60% after increasing the culture pH by the
addition of NaOH, and by 30% after denaturing
H2O2 with catalase. Thus, production of lactic
acid, which was mainly responsible for the low
pH, and, to a lesser degree, production of H2O2 by
L. acidophilus, affected the growth inhibition of
G. vaginalis signiﬁcantly. Klebanoff et al. [28]
found that H2O2-producing lactobacilli at high
concentrations inhibited the growth of G. vaginalis
and Bacteroides bivius. Catalase inhibited the tox-
icity of H2O2-producing lactobacilli, but not that of
non-H2O2-producing lactobacilli. Lower concen-
trations of H2O2-producing lactobacilli were toxic
for G. vaginalis, but only when combined with
myeloperoxidase and chloride, which have both
been found in cervical mucus. The highest toxicity
of this combination was obtained at pH 5–6. A pH
of £4.5 had, by itself, an inhibitory effect on the
growth of G. vaginalis, which was increased when
the above combination was added.
Finally, production of bacteriocins by some
Lactobacillus strains has also been found to play a
role in the inhibition of growth of G. vaginalis, at
least in vitro. Aroutcheva et al. [29] tested 22
Lactobacillus strains and found that 80% produced
a bacteriocin that inhibited the growth of G. vag-
inalis. Simoes et al. [30] showed that the growth of
28 (78%) of 36 clinical isolates of G. vaginalis was
inhibited by a bacteriocin-producing L. acidophilus
strain, and characterised these G. vaginalis isolates
as bacteriocin-susceptible.
CLINICAL TRIALS
Several clinical trials have been performed to
investigate whether speciﬁc strains of lactobacilli,
administered either orally or intra-vaginally, are
able to colonise the vaginas of women with
symptomatic or asymptomatic BV, to reduce the
colonisation of pathogens, and to improve symp-
toms and ⁄ or signs of BV when they are present.
Table 1 summarises the main characteristics and
outcomes of randomised controlled trials (RCTs)
that have been conducted with the aforemen-
tioned purpose.
Some RCTs have suggested that intra-vaginal
administration of L. acidophilus for 6–7 days cures
womenwith BV signiﬁcantlymore frequently than
administration of a placebo, administration of
acetic acid, or no treatment. Cure of BV was
deﬁned by the absence or presence of only one of
Amsel’s criteria, which are vaginal ﬂuid with a pH
>4.5, a thin homogeneous greyish-white adherent
discharge, a ﬁshy odour on addition of potassium
hydroxide 10% w ⁄ v to the discharge (a positive
amine test or sniff ⁄whiff test), and clue cells on a
saline wet mount [31]. Hallen et al. [32] found that
signiﬁcantly more women with BV were cured
7–10 days after the start of treatment with
L. acidophilus when compared with those treated
with a placebo. Restoration of a normal vaginal
microbiota was established in signiﬁcantly more
(57%, 16 ⁄ 28) women with BV who were treated
with L. acidophilus than in those receiving a placebo
(none of 29). Another RCT involving pregnant
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Table 1. Summary of randomised clinical trials of the use of probiotics in patients with bacterial vaginosis (BV)
Study
Number
of women
studied
Study
population
Treatment
OutcomeLactobacilli Control
Fredricsson et al. [39] 61 Women with
BV (‡3 ⁄ 4
Amsel’s
criteriaa
positive)
Group 1 (n = 14):
5 mL of
fermented milk
product with
Lactobacillus
acidophilus
(5 · 108 to
2 · 109 CFU ⁄mL)
intra-vaginally
twice-daily for
1 week
Group 2 (n = 17):
acetic acid jelly
intra-vaginally
5 mL 0.92% v ⁄v
twice-daily for
1 week Group 3
(n = 16): oestrogen
intra-vaginally
5 mL cream
twice-daily for
1 week Group 4
(n = 14): tablets
metronidazole
500 mg
intra-vaginally
twice-daily for
1 week
Cure (0–1 Amsel’s criteria) 4 weeks after start of treatment:
Group 1: 1 ⁄ 14 (7.1%)
Group 2: 3 ⁄ 17 (17.6%)
Group 3: 1 ⁄ 16 (6.3%)
Group 4: 13 ⁄ 14 (92.9%)
No. of aerobic isolates: signiﬁcant reduction 4 weeks after
start of treatment in groups 2, 3 and 4
No. of anaerobic isolates: signiﬁcant reduction 4 weeks
after start of treatment only in group 4
No. of aerobic species: signiﬁcant reduction 4 weeks after
start of treatment in all groups
No. of anaerobic species: signiﬁcant reduction 4 weeks
after start of treatment except for group 2
Hallen et al. [32] 57 Women with
BV (‡3 ⁄ 4
Amsel’s
criteria
positive)
Capsules of
(H2O2-producing)
L. acidophilus
(108)109
CFU ⁄ capsule)
intra-vaginally
twice-daily for
6 days (n = 28)
n = 29 (placebo) Presence of BV 7–10 days after start of treatment: 12 ⁄ 28
(43%) lactobacilli-treated vs. 29 ⁄ 29 (100%) placebo-treated, p <0.005
No signiﬁcant difference between lactobacilli- and
placebo-treated regarding the detection of
Mobiluncus and G. vaginalis in the vaginal samples
7–10 days after start of treatment
Detection of Bacteroides in vaginal samples: before
treatment: 26 ⁄ 28 (93%) lactobacilli-treated vs.
28 ⁄ 29 (97%) placebo-treated, p >0.05; 7–10 days after
start of treatment: 10 ⁄ 26 (38.4%)
lactobacilli-treated vs. 27 ⁄ 28 (96.4%) placebo-treated, p <0.005
Detection of vaginal lactobacilli: before treatment:
12 ⁄ 28 (43%) lactobacilli-treated vs. 9 ⁄ 29 (31%)
placebo-treated, p >0.05; 7–10 days after start of
treatment: 18 ⁄ 28 (64%) lactobacilli-treated vs.
11 ⁄ 29 (38%) placebo-treated, p <0.05
Neri et al. [33] 84 Women aged
25–31 years
with BV
(‡3 ⁄ 4
Amsel’s
criteria
positive,
ﬁrst
trimester
of
pregnancy
Group 1 (n = 32):
intra-vaginally
10–15 mL
of yoghurt with
L. acidophilus
(>108 ⁄mL)
twice-daily for
7 days and
repetition after
1 week
Group 2 (n = 32):
intra-vaginally
tampons with
10–15 mL of 5%
acetic acid and
repetition after
1 week
Group 3 (n = 20):
no treatment
Subjective clinical improvement on second day after
start of treatment: group 1: 32 ⁄ 32 (100%), group 2: 20 ⁄ 32 (62.5%),
group 3: 0 ⁄ 20 (0%), p <0.0005
Cure of BV (0–1 Amsel’s criteria) 1 month after end of
second treatment: group 1: 28 ⁄ 32 (87.5%), group 2: 12 ⁄ 32 (37.5%),
group 3: 3 ⁄ 20 (15%); group 1 vs. group 2: p 0.04; group 1 vs. group 3:
p <0.0005; group 2 vs. group 3: p >0.05
Cure of BV 2 months after end of second treatment: group 1: 28 ⁄ 32
(87.5%), group 2: 12 ⁄ 32 (37.5%), group 3: 1 ⁄ 20 (5%), p <0.05; group 1
vs. group 2: p 0.04; group 1 vs. group 3: p <0.0005; group 2 vs. group 3:
p <0.005
Parent et al. [34] 32 Pre-menopausal
women with
BV (‡2 Amsel’s
criteria positive,
6–30 vaginal
lactobacilli
per ﬁeld
of view (1000·
magniﬁcation),
eight pregnant
1–2 vaginal
tablets ⁄day with
50 mg of
H2O2-producing
L. acidophilus
(‡107 CFU ⁄ tablet)
and oestriol
(0.03 mg ⁄ tablet)
(Gynoﬂor) for
6 days (n = 17
n = 15 (placebo) Cure of BV (positive: £1 ⁄ 4 Amsel’s criteria):
2 weeks after start of treatment: 10 ⁄ 13 (76.9%)
lactobacilli-treated vs. 3 ⁄ 12 (25%) placebo, p <0.05;
4 weeks after start of treatment: 7 ⁄ 8 (87.5%)
lactobacilli-treated vs. 2 ⁄ 9 (22.2%) placebo, p <0.05
>30 vaginal lactobacilli per ﬁeld of view
(1000· magniﬁcation):
2 weeks after start of treatment: 7 ⁄ 11 (63.6%)
lactobacilli-treated vs. 1 ⁄ 10 (10%) placebo, p <0.05;
4 weeks after start of treatment: 7 ⁄ 8 (87.5%)
lactobacilli-treated vs. 1 ⁄ 7 (14.3%) placebo, p <0.01
Shalev et al. [41] 46 Women with
recurrent
vaginitis
(‡4
episodes
during the
year prior
to the
study, 20
women with
BV and
eight
women with
VVC and BV
at the
start of
the study)
Group 1 (n = 23):
150 mL ⁄day yoghurt
with L. acidophilus
for 2 months + no
yoghurt for the next
2 months + 150 mL ⁄day
pasteurised yoghurt for
the last 2 months
Group 2 (n = 23):
150 mL ⁄day
pasteurised yoghurt
for 2 months + no
yoghurt for the next
2 months + 150 mL ⁄day
yoghurt with
L. acidophilus
for the last 2 months
Women with positive L. acidophilus culturesb:
before treatment: 20% (group 1) vs. 31% (group 2);
after 1 month: 71% (group 1) vs. 27% (group 2), p <0.05;
after 2 months: 92% (group 1) vs. 27% (group 2), p <0.05
Women with BV (3 ⁄ 4 Amsel’s criteria-positive: pH >4.5,
positive amine test, clue cells)b:
before treatment: 56% (group 1) vs. 68% (group 2);
after 1 month: 24% of 21 women (group 1) vs. 52% of
19 women (group 2), p <0.05
after 2 months: 6% of 14 women (group 1) vs. 43% of
14 women (group 2), p <0.05
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Table 1. Continued
Study
Number
of women
studied
Study
population
Treatment
OutcomeLactobacilli Control
Reid et al. [44] 42 Women with no
symptoms of
urogenital infection
at entry into the
study (seven women
reported history of
BV, 14 women had
asymptomatic BV,
based on Nugent
score)
Group 1 (n = 10):
L. rhamnosus GR-1 ⁄
L. fermentum RC-14
8 · 108 ⁄day orally
for 28 days Group 2
(n = 12): L. rhamnosus
GR-1 ⁄ L. fermentum
RC-14 1.6 · 109 ⁄day
orally for 28 days
Group 3 (n = 11):
L. rhamnosus
GR-1 ⁄ L. fermentum
RC-14 6 · 109 ⁄day
orally for 28 days
GG 1010 ⁄day for
28 days
Conversion from BV Nugent scorec (at the start of the study)
to normal or intermediate Nugent score (at day 28): seven of 11 (64%) women
of groups 1, 2 and 3
Conversion from BV or intermediate ﬂora at the start of the
study to normal ﬂora on day 28: signiﬁcantly greater for group 2 than for
group 4, p 0.017
No symptoms of BV for 6 weeks
Reid et al. [42] 64 Women with no
urogenital infection
during the year
before the study
(16 women had
asymptomatic BV,
based on Nugent
score
L. rhamnosus
GR-1 + L. fermentum
RC-14
(>109 ⁄ strain ⁄ capsule
viable) orally
once-daily for
60 days (n = 32)
n = 32 (placebo) Restoration from BV to normal Nugent score: 37%
(lactobacilli-treated) vs. 13% (placebo), p 0.02
Vaginal lactobacilli count 28 and 60 days after start of
treatment: lactobacilli-treated > placebo (p 0.01)
Subjective improvement of vaginal health (vaginal
irritation, pain, odour, discharge, change of mucus 2 months after
start of the study: 30% (lactobacilli-treated) vs. 12%
(placebo), p 0.17
Reid et al. [43] 59 Pre-menopausal
women
without
urogenital
infections
during the
year prior
to the
study (15
women had
BV, based
on Nugent
score
L. rhamnosum GR-1
and L. fermentum
RC-14
(>109 ⁄ capsule
viable) orally
once-daily for
60 days (n = 29)
n = 30 (placebo) Change from BV (Nugent score 7–10) to normal or
intermediate vaginal microbiota (Nugent score
0–6) 2 months after start of the study: 7 ⁄ 8 (87.5%)
lactobacilli-treated vs. 0 ⁄ 7 (0%) placebo-treated, p <0.05
Subjective improvement of vaginal health 2 months
after start of the study (compared with start of the study): no vaginal
itchiness, 45% lactobacilli vs. 20% placebo (p <0.01), no vaginal
odour or discharge, 27% lactobacilli vs. 20% placebo, no limit to
intimate contact, 27% lactobacilli vs. 20% placebo; no hesitancy with
regard to having sex, 36% lactobacilli vs. 30% placebo
Ozkinay et al. [35] 360 Women
aged
17–65 years
with
vaginal
infections
(19 women
with BV)
One vaginal
tablet ⁄day of live
L. acidophilus
(‡107 CFU ⁄ tablet)
and oestriol
(0.03 mg ⁄ tablet)
and lactose
(600 mg ⁄ tablet)
(Gynoﬂor) for
6 days (for
post-menopausal
women) (n = 240)d
n = 120d (placebo) No signiﬁcant improvement of vaginal symptoms
(discharge, burning, itching, vulvar ⁄vaginal
inﬂammation, dyspareunia) (both lactobacilli- and
placebo-treated)
Normal ﬂora indexe increased signiﬁcantly more in
lactobacilli-treated than in placebo-treated (p 0.002 and p 0.006, 3–7 days
and 4–6 weeks after end of treatment, respectively; degree of purity
of vaginal ﬂorae increased signiﬁcantly more in lactobacilli-treated than
in placebo-treated (p <0.0001 and p 0.001, 3–7 days and 4–6 weeks after
end of treatment, respectively)
Eriksson et al. [40] 187 Women aged
18–53 years
with BV
(‡3 Amsel’s
criteria
positive,
68.4%
(128 ⁄ 187):
Nugent
score >6)
Tampons with
L. gasseri,
L. casei var.
rhamnosus
and L. fermentum
for ‡5 days
(n = 91)f
n = 96f (placebo) Cure rate after second menstruation:
Amsel’s criteria 0 ⁄ 4: 56% (lactobacilli-treated) vs. 62.5%
(placebo), p >0.05
Nugent score £3 (percentage of women with Nugent
score >6 before treatment: 54.4% (lactobacilli-treated) vs. 64.2% (placebo),
p >0.05
aAmsel’s criteria are: vaginal ﬂuid with pH >4.5; thin, homogeneous, greyish-white adherent discharge; ﬁshy odour on addition of potassium hydroxide 10% w ⁄v to the
discharge (positive amine test or sniff ⁄whiff test); and clue cells on saline wet mount.
bThe percentages are estimated approximately based on Figs 1 and 3 of Shalev et al. [41].
cPoints 1 to 4+ are allocated to each of the following morphotypes: lactobacilli (large Gram-positive rods), Gardnerella vaginalis (small Gram-variable rods), Bacteroides spp.
(small Gram-negative rods) andMobiluncus spp. (curved Gram-variable rods). Nugent score after adding the points: 0–3, normal lactobacilli-dominant vaginal microbiota; 4–6,
intermediate vaginal microbiota; and 7–10, BV.
dLactobacilli or placebo were administered 2–3 days after the end of anti-infective therapy (oral metronidazole for trichomoniasis and BV; oral ﬂuconazole ± local
ketoconazole for candidiasis).
eNormal ﬂora index (NFI) was calculated by allocating a value from 0 to 3 to each of the following parameters: number of lactobacilli, number of leukocytes, number of
pathogenic microorganisms and pH of vaginal secretion, and then adding the values together. The higher the NFI, the healthier the vaginal ﬂora. The degree of purity of the
vaginal ﬂora (lactobacillary grade) was estimated as follows: grade I, dominant lactobacilli, no other bacteria; grade II, lactobacilli and other bacteria; grade III, few or no
lactobacilli and other bacteria; and grade IV, no lactobacilli, no other bacteria.
fLactobacilli or placebo were administered during the menstruation period following administration of clindamycin 100 mg ⁄day vaginally for 3 days.
VVC, vulvovaginal candidiasis.
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women with BV showed that signiﬁcantly more
women treated with L. acidophilus intra-vaginally
were cured of BV at both 1 and 2 months after the
end of treatment when compared with women
treated with acetic acid or given no treatment [33].
Parent et al. [34] found that cure was more com-
mon, and the number of vaginal lactobacilli was
signiﬁcantly higher, in women with BV at both 2
and 4 weeks after the start of a 6-day treatment
with L. acidophilus and oestriol, when compared
with women with BV who received a placebo.
Ozkinay et al. [35] suggested that a healthier
vaginal microbiota, consisting of higher numbers
of lactobacilli and lower numbers of pathogenic
bacteria, was established in women who had
received L. acidophilus intra-vaginally and oestriol
for 6–12 days, compared with those receiving a
placebo, 2 or 3 days after the end of treatment of
BV or trichomoniasis with oral metronidazole,
and of vaginal candidiasis with oral ﬂuconazole
with or without local ketoconazole. However, no
signiﬁcant improvement of vaginal symptoms
was observed for either group of patients.
A prospective cohort study by Chimura et al.
[36] also yielded positive results regarding the
effect of intra-vaginal administration of yoghurt
containing Lactobacillus for 11 women with BV. A
statistically signiﬁcant reduction in vaginal
inﬂammation, discharge and vaginal pH was
found, and all 14 Gram-negative strains isolated
initially had disappeared 3 days after treatment.
Bacteriologically, BV was eradicated in six
(54.5%) of the 11 women, and was partly erad-
icated in three (27.3%). Two other prospective
cohort studies [37,38] administered L. acidophilus
intra-vaginally in combination with vitamin B
complex or oestriol to women with vaginitis, but
it was not mentioned whether the women includ-
ed in this latter study had BV.
In contrast, several other RCTs have failed to
detect a signiﬁcant difference in the cure rates for
women with BV, and have detected no signiﬁcant
change in the number of vaginal lactobacilli, after
intra-vaginal treatment with speciﬁc strains of
lactobacilli, and vaginal metronidazole was found
to be signiﬁcantly more effective than lactobacilli
in curing BV in one study. Fredricsson et al. [39]
found that instillation of L. acidophilus into the
vaginas of 14 women with BV cured only one
(7.1%) subject, while vaginal metronidazole tab-
lets cured 92.9%, and vaginal acetic acid jelly
cured 17.6% of the women with BV who were
treated with each regimen. Moreover, treatment
with L. acidophilus did not increase the number of
vaginal lactobacilli isolates. Subsequently, Eriks-
son et al. [40] used vaginal clindamycin to treat
187 women with BV, and then administered
L. gasseri, Lactobacillus casei var rhamnosus and
Lactobacillus fermentum, or a placebo, intra-vagin-
ally during the following menstruation cycle. The
BV cure rate after the second menstruation, as
deﬁned by either Amsel’s criteria or Nugent’s
score, did not differ signiﬁcantly for the women
treated with the tested lactobacilli when com-
pared with those treated with a placebo.
Oral administration of L. acidophilus, Lactobacillus
rhamnosus GR-1 and L. fermentum RC-14 for
2 months has been found in other RCTs to be
more effective than a placebo in preventing recur-
rences of BV and ⁄ or increasing vaginal colonisa-
tion with lactobacilli, thus restoring the normal
vaginal microbiota. Of 46 women with recurrent
vaginitis participating in a study by Shalev et al.
[41], 28 had BV, but only seven completed the
study. The percentage of women with positive
L. acidophilus vaginal cultures after 1 month and
after 2 months increased among women receiving
yoghurt containing L. acidophilus during the ﬁrst
2 months of the study, and was signiﬁcantly
higher than for women receiving pasteurised
yoghurt during the same period. Moreover, epi-
sodes of BV after 1 and after 2 months decreased
signiﬁcantly in women who consumed yoghurt
containing L. acidophilus during the ﬁrst 2 months
of the study when compared with the episodes of
BV among women consuming pasteurised yog-
hurt during the same period [41].
Reid et al. [42] found that the numbers of vaginal
lactobacilli showed a signiﬁcant increase in 32
healthy women receiving L. rhamnosus GR-1 and
L. fermentum RC-14 orally on a daily basis for 2 and
4 weeks compared with 32 healthy women taking
a placebo. The vaginal microbiota was restored
from asymptomatic BV to a normal Nugent score
in signiﬁcantly more women receiving lactobacilli
than in placebo-treated women. A similar result
was obtained in a second RCT involving 59women
treatedwith either the same lactobacilli at the same
dosage and for the same period or with a placebo
[43]. The dose of lactobacilli required to restore
and maintain a normal (based on Nugent score)
vaginal microbiota was found to be >108 viable
L. rhamnosusGR-1 and L. fermentum RC-14 daily in
a trial involving 42 healthy women [44].
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Finally, L. acidophilus was administered intra-
muscularly in a small prospective cohort study by
Pattman et al. [45]. Three 0.5-mL injections at
2-weekly intervals were administered to eight
women with recurrent BV (more than two epi-
sodes during the 6-month period preceding the
study) who had been treated with oral metroni-
dazole. Six women were treated concurrently
with metronidazole. Four (50%) of these women
had no episodes of BV for 6 months, two had a
recurrence of BV within 3 months of completing
treatment, but had no more episodes after being
treated with metronidazole, and one had two
recurrences, received one additional injection
with L. acidophilus, and remained asymptomatic
for the following 6 months. Clue cells were
replaced by lactobacilli in all women who report-
ed improvement of their symptoms.
CONCLUSIONS
Various in-vitro studies have shown that speciﬁc
strains of lactobacilli inhibit the growth of bacteria
causing BV by producing H2O2, lactic acid,
and ⁄ or bacteriocins, and ⁄ or inhibit the adherence
of G. vaginalis to the vaginal epithelium. Most
relevant clinical trials have suggested that oral
administration of L. acidophilus, or intra-vaginal
administration of L. acidophilus or L. rhamnosus
GR-1 and L. fermentum RC-14, is able to increase
the numbers of vaginal lactobacilli, restore the
vaginal microbiota to normal, and cure women
of BV, although several trials found that intra-
vaginal instillation of lactobacilli had no signiﬁ-
cant effect on the treatment of BV. In most of the
relevant RCTs, lactobacilli were compared with a
placebo, in two RCTs with acetic acid, and in one
RCT with no treatment. Interestingly, in only one
RCT [39] were lactobacilli compared with met-
ronidazole. However, further RCTs, including
larger samples of women with BV, in which
lactobacilli are compared either with a placebo or
metronidazole, need to be conducted before it will
be possible to reach deﬁnitive conclusions as to
whether probiotics represent an effective and safe
method for treating women with BV.
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